345 related articles for article (PubMed ID: 18177204)
1. Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41.
Blish CA; Nguyen MA; Overbaugh J
PLoS Med; 2008 Jan; 5(1):e9. PubMed ID: 18177204
[TBL] [Abstract][Full Text] [Related]
2. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
[TBL] [Abstract][Full Text] [Related]
3. Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape.
Wibmer CK; Gorman J; Ozorowski G; Bhiman JN; Sheward DJ; Elliott DH; Rouelle J; Smira A; Joyce MG; Ndabambi N; Druz A; Asokan M; Burton DR; Connors M; Abdool Karim SS; Mascola JR; Robinson JE; Ward AB; Williamson C; Kwong PD; Morris L; Moore PL
PLoS Pathog; 2017 Jan; 13(1):e1006074. PubMed ID: 28076415
[TBL] [Abstract][Full Text] [Related]
4. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
[TBL] [Abstract][Full Text] [Related]
5. Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein.
Ye L; Sun Y; Lin J; Bu Z; Wu Q; Jiang S; Steinhauer DA; Compans RW; Yang C
Virology; 2006 Aug; 352(1):74-85. PubMed ID: 16725170
[TBL] [Abstract][Full Text] [Related]
6. Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity.
Bradley T; Trama A; Tumba N; Gray E; Lu X; Madani N; Jahanbakhsh F; Eaton A; Xia SM; Parks R; Lloyd KE; Sutherland LL; Scearce RM; Bowman CM; Barnett S; Abdool-Karim SS; Boyd SD; Melillo B; Smith AB; Sodroski J; Kepler TB; Alam SM; Gao F; Bonsignori M; Liao HX; Moody MA; Montefiori D; Santra S; Morris L; Haynes BF
EBioMedicine; 2016 Oct; 12():196-207. PubMed ID: 27612593
[TBL] [Abstract][Full Text] [Related]
7. Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.
Park EJ; Vujcic LK; Anand R; Theodore TS; Quinnan GV
J Virol; 1998 Sep; 72(9):7099-107. PubMed ID: 9696803
[TBL] [Abstract][Full Text] [Related]
8. Association of enhanced HIV-1 neutralization by a single Y681H substitution in gp41 with increased gp120-CD4 interaction and macrophage infectivity.
Ringe R; Bhattacharya J
PLoS One; 2012; 7(5):e37157. PubMed ID: 22606344
[TBL] [Abstract][Full Text] [Related]
9. Antibody neutralization and escape by HIV-1.
Wei X; Decker JM; Wang S; Hui H; Kappes JC; Wu X; Salazar-Gonzalez JF; Salazar MG; Kilby JM; Saag MS; Komarova NL; Nowak MA; Hahn BH; Kwong PD; Shaw GM
Nature; 2003 Mar; 422(6929):307-12. PubMed ID: 12646921
[TBL] [Abstract][Full Text] [Related]
10. Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein.
Edwards TG; Hoffman TL; Baribaud F; Wyss S; LaBranche CC; Romano J; Adkinson J; Sharron M; Hoxie JA; Doms RW
J Virol; 2001 Jun; 75(11):5230-9. PubMed ID: 11333905
[TBL] [Abstract][Full Text] [Related]
11. A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.
Park EJ; Gorny MK; Zolla-Pazner S; Quinnan GV
J Virol; 2000 May; 74(9):4183-91. PubMed ID: 10756031
[TBL] [Abstract][Full Text] [Related]
12. Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change.
Thali M; Charles M; Furman C; Cavacini L; Posner M; Robinson J; Sodroski J
J Virol; 1994 Feb; 68(2):674-80. PubMed ID: 7507184
[TBL] [Abstract][Full Text] [Related]
13. Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution.
Shen X; Dennison SM; Liu P; Gao F; Jaeger F; Montefiori DC; Verkoczy L; Haynes BF; Alam SM; Tomaras GD
Proc Natl Acad Sci U S A; 2010 Mar; 107(13):5972-7. PubMed ID: 20231447
[TBL] [Abstract][Full Text] [Related]
14. Antibody neutralization escape mediated by point mutations in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41.
Kalia V; Sarkar S; Gupta P; Montelaro RC
J Virol; 2005 Feb; 79(4):2097-107. PubMed ID: 15681412
[TBL] [Abstract][Full Text] [Related]
15. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies.
Broder CC; Earl PL; Long D; Abedon ST; Moss B; Doms RW
Proc Natl Acad Sci U S A; 1994 Nov; 91(24):11699-703. PubMed ID: 7972127
[TBL] [Abstract][Full Text] [Related]
16. Regulation of epitope exposure in the gp41 membrane-proximal external region through interactions at the apex of HIV-1 Env.
Schapiro HM; Khasnis MD; Ahn K; Karagiaridi A; Hayden S; Cilento ME; Root MJ
PLoS Pathog; 2022 May; 18(5):e1010531. PubMed ID: 35584191
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
[TBL] [Abstract][Full Text] [Related]
18. The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.
Pinter A; Honnen WJ; D'Agostino P; Gorny MK; Zolla-Pazner S; Kayman SC
J Virol; 2005 Jun; 79(11):6909-17. PubMed ID: 15890930
[TBL] [Abstract][Full Text] [Related]
19. Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies.
O'Rourke SM; Schweighardt B; Phung P; Mesa KA; Vollrath AL; Tatsuno GP; To B; Sinangil F; Limoli K; Wrin T; Berman PW
J Virol; 2012 Nov; 86(22):12105-14. PubMed ID: 22933284
[TBL] [Abstract][Full Text] [Related]
20. Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites.
Watkins BA; Buge S; Aldrich K; Davis AE; Robinson J; Reitz MS; Robert-Guroff M
J Virol; 1996 Dec; 70(12):8431-7. PubMed ID: 8970964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
